SPC432
Spesólímab, mótefni gegn IL-36R
Status:
VeittApplication date:
31.5.2023Application published:
15.7.2023Grant published:
15.12.2024
Max expiry date:
13.5.2038Medicine name:
SpevigoMedicine for children:
Yes
Timeline
Today
31.5.2023Application
15.7.2023Publication
15.12.2024Registration
13.5.2038Expires
Marketing license
IS authorization number:
EU/1/22/1688Date:
3.1.2023
Foreign authorization number:
EU/1/22/1688Date:
9.12.2022
Owner
Name:
Boehringer Ingelheim International GmbHAddress:
Binger Strasse 173, Ingelheim am Rhein DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2780373
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 24.10.2024
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 10.10.2025